Market capitalization | CHF37.20b |
Enterprise Value | CHF40.08b |
P/E (TTM) P/E ratio | 36.33 |
EV/FCF (TTM) EV/FCF | 32.13 |
EV/Sales (TTM) EV/Sales | 4.65 |
P/S ratio (TTM) P/S ratio | 4.32 |
P/B ratio (TTM) P/B ratio | 2.07 |
Dividend yield | 0.32% |
Last dividend (FY23) | CHF0.24 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
29 Analysts have issued a Alcon forecast:
29 Analysts have issued a Alcon forecast:
Sep '24 |
+/-
%
|
||
Revenue | 8,621 8,621 |
1%
1%
|
|
Gross Profit | 4,781 4,781 |
1%
1%
|
|
EBITDA | 2,377 2,377 |
13%
13%
|
EBIT (Operating Income) EBIT | 1,291 1,291 |
28%
28%
|
Net Profit | 1,025 1,025 |
157%
157%
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.
Head office | Switzerland |
CEO | David Endicott |
Employees | 25,315 |
Founded | 1945 |
Website | www.alcon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.